Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Birgit E. P. J. Vriens"'
Autor:
Romy Aarnoutse, Janine Ziemons, Lars E. Hillege, Judith de Vos-Geelen, Maaike de Boer, Saskia M. P. Bisschop, Birgit E. P. J. Vriens, Jeroen Vincent, Agnes J. van de Wouw, Giang N. Le, Koen Venema, Sander S. Rensen, John Penders, Marjolein L. Smidt
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-13 (2022)
Abstract This clinical study explored the associations between the intestinal microbiota, chemotherapy toxicity, and treatment response in postmenopausal oestrogen receptor positive breast cancer patients.Oestrogen receptor positive postmenopausal br
Externí odkaz:
https://doaj.org/article/428760b3d68e44538ecc8341fa83aaa3
Autor:
Stefanie de Groot, Hanno Pijl, Ayoub Charehbili, Saskia van de Ven, Vincent T. H. B. M. Smit, Elma Meershoek-Klein Kranenbarg, Joan B. Heijns, Laurence J. C. van Warmerdam, Lonneke W. Kessels, M. Wouter Dercksen, Manon J. A. E. Pepels, Hanneke W. M. van Laarhoven, Birgit E. P. J. Vriens, Hein Putter, Marta Fiocco, Gerrit-Jan Liefers, Jacobus J. M. van der Hoeven, Johan W. R. Nortier, Judith R. Kroep, on behalf of the Dutch Breast Cancer Research Group
Publikováno v:
Breast Cancer Research, Vol 21, Iss 1, Pp 1-9 (2019)
Abstract Background Adjuvant bisphosphonates are associated with improved breast cancer survival in postmenopausal patients. Addition of zoledronic acid (ZA) to neoadjuvant chemotherapy did not improve pathological complete response in the phase III
Externí odkaz:
https://doaj.org/article/a99967db5d734f59a7bddc08f547d2ce
Autor:
Khava I. E. Ibragimova, Sandra M. E. Geurts, Marissa Meegdes, Frans Erdkamp, Joan B. Heijns, Jolien Tol, Birgit E. P. J. Vriens, Marcus W. Dercksen, Kirsten N. A. Aaldering, Manon J. A. E. Pepels, Linda van de Winkel, Natascha A. J. B. Peters, Nathalie J. A. Teeuwen-Dedroog, Ingeborg J. H. Vriens, Vivianne C. G. Tjan-Heijnen
Publikováno v:
Breast Cancer Research and Treatment, 198(2), 239-251. Springer, Cham
Purpose We assessed the systemic treatment choices and outcomes in patients diagnosed with human epidermal growth factor receptor-2-positive (HER2 +) advanced breast cancer (ABC), for the first four lines of systemic therapy and by hormone receptor (
Autor:
Marissa Meegdes, Khava I. E. Ibragimova, Dorien J. A. Lobbezoo, Ingeborg J. H. Vriens, Loes F. S. Kooreman, Frans L. G. Erdkamp, M. Wouter Dercksen, Birgit E. P. J. Vriens, Kirsten N. A. Aaldering, Manon J. A. E. Pepels, Linda M. H. van de Winkel, Jolien Tol, Joan B. Heijns, Agnes J. van de Wouw, Natascha A. J. B. Peters, Ananda Hochstenbach-Waelen, Marjolein L. Smidt, Sandra M. E. Geurts, Vivianne C. G. Tjan-Heijnen
Publikováno v:
Breast Cancer Research and Treatment, 192(2), 331-342. Springer, Cham
Purpose The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the disease course. This study aims to evaluate the biopsy rat
Autor:
Romy Aarnoutse, Lars E. Hillege, Janine Ziemons, Judith De Vos-Geelen, Maaike de Boer, Elvira M. E. R. Aerts, Birgit E. P. J. Vriens, Yvonne van Riet, Jeroen Vincent, Agnes J. van de Wouw, Giang N. Le, Koen Venema, Sander S. Rensen, John Penders, Marjolein L. Smidt
Publikováno v:
Cancers, Vol 13, Iss 6200, p 6200 (2021)
Cancers
Cancers; Volume 13; Issue 24; Pages: 6200
Cancers, 13(24):6200. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers
Cancers; Volume 13; Issue 24; Pages: 6200
Cancers, 13(24):6200. Multidisciplinary Digital Publishing Institute (MDPI)
Simple Summary Besides the already known factors that increase the risk of breast cancer, like hormonal treatment, heredity, and obesity, growing evidence exists that intestinal microbiota can influence breast cancer carcinogenesis. Current clinical
Autor:
Marissa, Meegdes, Sandra M E, Geurts, Frans L G, Erdkamp, Marcus Wouter, Dercksen, Birgit E P J, Vriens, Kirsten N A, Aaldering, Manon J A E, Pepels, Linda M H, van de Winkel, Nathalie J A, Teeuwen, Maaike, de Boer, Vivianne C G, Tjan-Heijnen
Publikováno v:
International journal of cancer. 150(1)
In August 2017, cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy have been reimbursed in the Netherlands for patients with hormone receptor positive (HR+), HER2 negative (HER2-) advanced breast cancer (ABC). This study
Autor:
Paul P Schneider, Xavier G L V Pouwels, Valéria Lima Passos, Bram L T Ramaekers, Sandra M E Geurts, Khava I E Ibragimova, Maaike de Boer, Frans Erdkamp, Birgit E P J Vriens, Agnes J van de Wouw, Marien O den Boer, Manon J Pepels, Vivianne C G Tjan-Heijnen, Manuela A Joore
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0230909 (2020)
OBJECTIVE:In breast cancer patients, treatment at the end of life accounts for a major share of medical spending. However, little is known about the variability of cost trajectories between patients. This study aims to identify underlying latent grou
Externí odkaz:
https://doaj.org/article/c542a7f020294eb2862b4ef478cfa91e